Efficacy and Tolerability of Selexipag in Pediatric Patients with Pulmonary Arterial Hypertension: An Updated Systematic Review and Meta-analysis
Pediatric Cardiology · 2026
DOI: 10.1007/s00246-025-04094-y ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pediatric Cardiology, 2026. Verfasst von Vasiliki Patsiou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Hypertension and Congenital Heart Disease Unit, AHEPA University General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Gree…. Hauptthemen laut MEDLINE: Pyrazines, Acetamides, Antihypertensive Agents, Pulmonary Arterial Hypertension. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Evidence supporting selexipag in pediatric pulmonary arterial hypertension (PAH) is sparse, mainly from small, heterogeneous studies. This meta-analysis assessed its efficacy and tolerability in this population. A systematic search of PubMed, Embase, Web of Science, Cochrane Library, and Scopus was conducted until April 2025. Eligible studies included patients under 18 years diagnosed with PAH and treated with selexipag, reporting clinical outcomes. Two reviewers independently screened, extracted data, and evaluated study quality. Pooled analyses of efficacy and safety outcomes were performed, with subgroup comparisons for add-on therapy versus transition from parenteral prostacyclin analogs. Twelve studies involving 344 pediatric patients (90.6% diagnosed with PAH) were included. Selexipag significantly improved 6-minute walk distance (SMD: - 0.75; 95% CI: - 1.22 to - 0.29; P = 0.002), but did not affect pulmonary vascular resistance index, mean pulmonary artery pressure (mPAP), or NT-proBNP. Sensitivity analysis revealed reduced mPAP in PAH-only studies (SMD: - 0.30; P = 0.03). Adverse events occurred in 62.8%, predominantly mild. Functional improvement was greater in the add-on therapy group, which also experienced more adverse events. Selexipag improved functional capacity and mPAP in pediatric PAH and was generally well tolerated. Further prospective studies are needed to confirm long-term benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Hypertension and Congenital Heart Disease Unit, AHEPA University General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, New York, USA.
- Elmezzi Graduate School of Molecular Medicine, Northwell Health, Manhasset, NY, USA.
- Pediatric Cardiology Unit, 3rd Department of Pediatrics, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- 2nd Cardiology Department, Hippokrateion General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK.
Zitieren
APA
Patsiou, V., Grantza, T., Chrysochoidis-Trantas, T., Kavga, M., Fragakis, N., Ziakas, A., Arvanitaki, A., & Giannakoulas, G. (2026). Efficacy and Tolerability of Selexipag in Pediatric Patients with Pulmonary Arterial Hypertension: An Updated Systematic Review and Meta-analysis. Pediatric Cardiology. https://doi.org/10.1007/s00246-025-04094-y
Vancouver
Patsiou V, Grantza T, Chrysochoidis-Trantas T, Kavga M, Fragakis N, Ziakas A, et al. Efficacy and Tolerability of Selexipag in Pediatric Patients with Pulmonary Arterial Hypertension: An Updated Systematic Review and Meta-analysis. Pediatric Cardiology. 2026. doi:10.1007/s00246-025-04094-y
BibTeX
@article{Patsiou2026,
author = {Patsiou, Vasiliki and Grantza, Triantafyllia and Chrysochoidis-Trantas, Thomas and Kavga, Maria and Fragakis, Nikolaos and Ziakas, Antonios and Arvanitaki, Alexandra and Giannakoulas, George},
title = {Efficacy and Tolerability of Selexipag in Pediatric Patients with Pulmonary Arterial Hypertension: An Updated Systematic Review and Meta-analysis},
journal = {Pediatric Cardiology},
year = {2026},
doi = {10.1007/s00246-025-04094-y}
}
EUVIMED